Last reviewed · How we verify

Methylprednisone — Competitive Intelligence Brief

Methylprednisone (Methylprednisone) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Other.

phase 2 Glucocorticoid receptor Other Small molecule Live · refreshed every 30 min

Target snapshot

Methylprednisone (Methylprednisone) — Dana-Farber Cancer Institute.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Methylprednisone TARGET Methylprednisone Dana-Farber Cancer Institute phase 2 Glucocorticoid receptor
Durezol DIFLUPREDNATE Novartis marketed difluprednate Glucocorticoid receptor 2008-01-01
Arnuity Ellipta FLUTICASONE FUROATE Haleon Us Holdings marketed Corticosteroid Glucocorticoid receptor 2007-01-01
Omnaris CICLESONIDE Covis marketed ciclesonide Glucocorticoid receptor 2006-01-01
Omnaris Alvesco Takeda Gmbh marketed ciclesonide Glucocorticoid receptor 2006-01-01
Mifeprex MIFEPRISTONE Corcept Therap marketed Progestin Antagonist [EPC] Glucocorticoid receptor 2000-01-01
Lotemax LOTEPREDNOL ETABONATE Bausch Health marketed Corticosteroid Glucocorticoid receptor 1998-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Methylprednisone — Competitive Intelligence Brief. https://druglandscape.com/ci/methylprednisone. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing